Home›Stock Screener›IPCA Laboratories

IPCA Laboratories Share Price Today | Stock Price & IPCA Laboratories Share Screener

IPCALAB Pharmaceuticals & Biotechnology
Live Share Price NSE
₹1860.00
▲ 5.90 (0.32%)
2026-11-19 00:00:00
Live Share Price BSE
₹1859.75
▲ 5.55 (0.30%)
2026-11-19 00:00:00

As of November 19, 2026, the live IPCA Laboratories share price (NSE: IPCALAB) is ₹1,860.00 on NSE and ₹1,859.75 on BSE, up 0.32% from the previous close, with shares trading between ₹1,845.10 and ₹1,890.50 in today's trading session, and a 52-week range of ₹1,385.80–₹2,009.60. Track IPCALAB market value to gauge the company's total market size. Use the IPCA Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today IPCA Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹2,482 and net income of ₹307, with EBITDA of ₹532, an operating margin of 18.0% and a profit margin of 12.4%.

IPCA Laboratories Market Cap ₹47,797.87 Cr.
IPCALAB P/E Ratio (TTM) 32.50
IPCA Laboratories P/B Ratio 5.56
EPS (TTM) ₹44.98
Dividend Yield 0.32%
Debt to Equity 0.14
IPCALAB 52 Week High ₹2009.60
IPCA Laboratories 52 Week Low ₹1385.80
Operating Margin 18.00%
Profit Margin 12.37%
IPCALAB Revenue (TTM) ₹2,482.00
EBITDA ₹532.00
Net Income ₹307.00
Total Assets ₹12,370.00
Total Equity ₹9,524.00

IPCA Laboratories Share Price Chart

Track the current stock price of IPCA Laboratories with an interactive chart. Analyse IPCALAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete IPCA Laboratories stock quote in one place.

The quote of ₹1,860.00 sits between the 52-week low of ₹1,385.80 and the 52-week high of ₹2,009.60, and the latest session moved 0.32% from the previous close.

IPCA Laboratories Company Profile - Fundamental Screener

Screen IPCA Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for IPCALAB shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Premchand Godha listed as chairperson or CEO, and it trades under ISIN INE571A01038.

Business Overview

Ipca Laboratories Limited is an Indian integrated pharmaceutical company that manufactures and markets over 350 formulations and 80 active pharmaceutical ingredients (APIs) across various therapeutic segments. The company operates 18 manufacturing units in India and sells its products in over 100 countries worldwide. Ipca specializes in producing APIs such as...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO Premchand Godha
ISIN INE571A01038

IPCA Laboratories Balance Sheet Screener

Screen IPCALAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹12,370, up from ₹11,761 in 2025.

Latest statistics put total assets at ₹12,370 and shareholder funds at ₹9,524, with a leverage ratio of 0.14.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 12,370 11,761 11,101 8,626 7,639 6,068 5,260 4,551 4,117 3,960
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 4,627 4,267 4,553 2,751 2,418 2,072 2,059 1,940 1,953 1,983

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 539 986 1,019 905 604 192 292 315 421 548
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 9,524 8,388 7,727 5,915 5,569 4,716 3,641 3,138 2,689 2,455
Share Capital 25 25 25 25 25 25 25 25 25 25
Reserves & Surplus 8,038 6,923 6,307 5,817 5,467 4,676 3,590 3,097 2,663 2,430

IPCA Laboratories Income Statement Screener - Profit & Revenue Analysis

Screen IPCA Laboratories income statement and profit fundamentals. Analyze IPCALAB quarterly results. IPCA Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹2,482 and net profit was ₹307, equal to earnings per unit of ₹13.31, at an operating margin of 18%.

In that period expenses were ₹1,950, interest cost ₹20 and tax ₹98. The next period listed, 2026-Jun, shows revenue of ₹2,813 and net profit of ₹424.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 2,482 2,813 2,935 2,273 2,342 2,584 2,430 2,052 2,113 2,381 2,266 1,548 1,630 2,073 2,144
Expenses 1,950 2,119 2,261 2,023 1,892 2,070 1,859 1,848 1,700 1,913 1,782 1,331 1,278 1,713 1,722

Operating Costs and Margins

EBITDA 532 695 674 250 449 515 571 204 413 468 483 217 353 360 422
Operating Profit % 18.00% 24.00% 22.00% 10.00% 18.00% 19.00% 22.00% 9.00% 19.00% 19.00% 21.00% 12.00% 19.00% 16.00% 16.00%
Depreciation 107 111 115 100 100 103 108 98 99 100 99 70 69 90 100
Interest 20 12 13 22 19 20 18 29 24 23 17 19 31 44 33

Profit and Earnings

Profit Before Tax 405 572 547 128 331 392 446 77 290 345 368 129 252 225 289
Tax 98 148 158 64 98 111 82 75 91 99 92 51 88 89 68
Net Profit 307 424 389 64 233 281 364 1 199 246 276 78 164 137 221
EPS 13.31 15.84 14.79 2.67 9.19 11.14 12.86 2.35 7.58 9.05 9.78 3.02 6.42 5.72 7.09

IPCA Laboratories Cash Flow Screener - Liquidity Fundamentals

Screen IPCALAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹1,142, and net cash flow was an inflow of ₹142.

Over the same period, investing activities used ₹247 and financing activities used ₹754.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 1,142 1,321 945 806 856 1,090 570 501 341 282
Investing Activities -247 -870 -1,215 -725 -851 -521 -509 -165 -135 -149

Financing and Net Cash

Financing Activities -754 -283 -553 507 427 -306 -137 -183 -130 -159
Net Cash Flow 142 169 -823 588 432 264 -76 153 75 -26

IPCA Laboratories Shareholding Pattern Screener

See IPCA Laboratories shareholding pattern with promoter, FII, and DII holdings. Check IPCA Laboratories promoter holding and ownership changes for IPCALAB on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 44.72%, foreign institutions 11.53%, domestic institutions 36.59% and the public 5.72%, spread across 90,514 shareholders.

The shareholder count was 90,514 in 2026-Sept, compared with 82,060 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec

Promoter Holding

Promoter Holding 44.72% 44.72% 44.72% 44.72% 44.72% 44.72% 44.72% 44.72%

Institutional Investors

FII Holding 11.53% 10.73% 10.63% 10.63% 10.43% 10.67% 10.76% 11.07%
DII Holding 36.59% 37.37% 37.45% 37.32% 36.77% 36.20% 36.06% 35.68%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 5.72% 5.76% 5.79% 5.88% 6.55% 6.82% 6.81% 6.88%
Other Holding 1.43% 1.42% 1.41% 1.44% 1.53% 1.59% 1.65% 1.65%
Shareholder Count 90,514 82,060 82,184 77,673 82,870 85,582 88,306 90,189

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by IPCA Laboratories. IPCA Laboratories dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹4.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹4.00 and ₹4.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹4.00 0.25%
2024-March ₹4.00 0.27%
2023-March ₹4.00 0.32%
2022-March ₹8.00 1.02%
2021-March ₹8.00 0.75%
2020-March ₹5.00 0.53%
2019-March ₹3.00 0.43%
2018-March ₹1.00 0.20%
2017-March ₹1.00 0.31%

IPCA Laboratories Stock Index Membership - Nifty & Sensex

See which indices include IPCA Laboratories stock. Check IPCALAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 22 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE 200 EQUAL WEIGHT, BSE INDEX BSE HC, BSE INDEX BSE200.

Complete Index List

BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MSL400
NIFTY 500
NIFTY HEALTHCARE
NIFTY LARGEMID250
NIFTY MIDCAP 150
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY PHARMA
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH
NIFTYM150MOMNTM50

IPCA Laboratories Market Events Screener - Corporate Actions

Get IPCA Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check IPCA Laboratories stock events that may affect IPCALAB share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.

It is followed by Quarterly Result Announcement dated August 13, 2026 and Annual General Meeting dated August 13, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-05 2026-11-05 Quarterly Result Announcement NA 2.77%
2026-08-13 2026-08-13 Quarterly Result Announcement NA -0.59%
2026-08-13 2026-08-13 Annual General Meeting NA -1.19%
2026-08-07 2026-08-07 Dividend ₹ 6.00 /share 10.24%
2026-05-29 2026-05-29 Quarterly Result Announcement NA 2.71%
2026-02-13 2026-02-13 Quarterly Result Announcement NA -0.54%
2025-11-13 2025-11-13 Quarterly Result Announcement NA 4.12%
2025-08-11 2025-08-11 Quarterly Result Announcement NA -5.30%
2025-08-11 2025-08-11 Annual General Meeting NA -4.14%
2025-08-05 2025-08-05 Dividend ₹ 2.00 /share -3.58%
2025-05-29 2025-05-29 Quarterly Result Announcement NA 6.52%
2025-02-13 2025-02-13 Quarterly Result Announcement NA -6.28%
2024-11-27 2024-11-27 Dividend ₹ 2.00 /share 3.99%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -3.83%
2024-08-13 2024-08-13 Annual General Meeting NA 13.43%

IPCA Laboratories Competitors Screener - Peer Stocks Comparison

Screen IPCALAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.20 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.40 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,632 85.50 13,886 20.34% 2,138 47.27
Laurus Labs 130,972 97.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 28.00 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 42.00 35,059 3.90% 4,158 70.24
Cipla 112,438 39.90 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.10 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,903 26.00 34,145 5.56% 3,503 66.06
Lupin 90,557 17.60 29,039 26.75% 5,356 44.92

IPCA Laboratories Company Announcements - News & Reports Screener

Screen IPCALAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 11, 2026.

The next most recent announcements are dated November 11, 2026 and November 10, 2026.

Date Update Actions
2026-11-11 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-11 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-10 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-10 Standalone And Consolidated Financial Results For Second Quarter And Half Year Ended 30.09.2026 -
2026-11-10 Board Meeting Outcome for Standalone And Consolidated Financial Results For Second Quarter And Half Year Ended 30.09.2026 -
2026-10-28 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-22 Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For The Second Quarter And Half Year Ended 30.09.2026 -
2026-10-12 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-22 Closure of Trading Window -
2026-08-17 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-08-14 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-08-14 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-14 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-08-13 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-08-13 Standalone And Consolidated Unaudited Financial Results For Q1FY27 -
2026-08-13 Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results For Q1FY27 -
2026-08-06 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-07-28 Board Meeting Intimation for Standalone And Consolidated Financial Results For 1St Quarter Ended 30Th June 2026 -
2026-07-17 Intimation Of Web Link To Non-Email Cases -
2026-07-15 Announcement under Regulation 30 (LODR)-Newspaper Publication -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,860.00, within a 52-week range of ₹1,385.80 to ₹2,009.60. The P/E ratio is 32.50 and the P/B ratio is 5.56, with earnings per unit of ₹44.98. Market capitalisation stands at ₹47,797.87 Cr and the dividend yield is 0.32%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.